| June 17, 2008 |
| June 18, 2008 |
| December 2007 |
| March 2008 (final data collection date for primary outcome measure) |
| Assessment of the blood pressure effect of a single dose of comparator alone versus comparator with investigational product in migraineurs. [ Time Frame: Up to 6 hours postdose. ] [ Designated as safety issue: No ] |
| Same as current |
| Complete list of historical versions of study NCT00701389 on ClinicalTrials.gov Archive Site |
| Assessment of the safety and tolerability of a single dose of comparator alone versus comparator with investigational product in migraineurs. Assessment of the blood pressure effect of a single dose of investigational product vs. placebo in migraineurs. [ Time Frame: Up to 6 hours postdose. ] [ Designated as safety issue: No ] |
| Same as current |
| |
| Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK0974 in Migraine Patients |
| A Double-Blind, Randomized, Placebo-Controlled, 3-Period, Single Dose Crossover Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK0974 in Migraine Patients |
Study to understand the effects of blood pressure in patients with migraine. |
| |
| Phase I |
| Interventional |
| Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Crossover Assignment, Safety Study |
| Migraine Disorders |
- Drug: MK0974
- Drug: sumatriptan
- Drug: placebo (unspecified)
|
- Experimental: drug-drug
- Active Comparator: drug placebo
- Experimental: placebo drug
- Placebo Comparator: placebo, placebo
|
| |
| |
| Completed |
| 24 |
| April 2008 |
| March 2008 (final data collection date for primary outcome measure) |
Inclusion Criteria:
- Patient has history of migraine for longer than 6 months.
- Patient is free from migraine 24 hours before each dosing.
- Patient is judged to be in good health.
- Nonsmoker
Exclusion Criteria:
- Under age of legal consent.
- Legally or mentally incapacitated or has significant emotional problems.
- Patient is taking any medications from about 2 weeks before the first dose of study medication.
- Patient has had surgery or donated blood or participated in another investigation study within 4 weeks prior to screening
- Patient is currently a regular user of any illicit drugs or has a history of drug/alcohol abuse within about 2 years
- Patient consumes more than 6 caffeinated beverages per day
|
| Both |
| 18 Years to 65 Years |
| No |
| Contact information is only displayed when the study is recruiting subjects |
|
| |
| NCT00701389 |
| Executive Vice President, Clinical and Quantitative Sciences, Merck & Co., Inc. |
| 2008_500, MK0974-026 |
| Merck |
|
| Study Director: |
Medical Monitor |
Merck |
|
|
| Merck |
| June 2008 |
